The objective of this study was to investigate the impact of travel distance to the treating facility on the risk of overall mortality (OM) among US patients with prostate cancer (PCa). METHODS: In total, 775,999 patients who had PCa in all stages and received treatment with different strategies (radical prostatectomy, radiation therapy, observation, androgen-deprivation therapy, multimodal treatment, and chemotherapy) were drawn from the National Cancer Data Base from 2004 through 2012. Independent predictors of travel distance (intermediate [12.5-49.9 miles] and long [49.9-249.9 miles] vs short[<12.5 miles]) and its effect on OM were calculated using multivariable regression analyses. Additional analyses evaluated the distance effect on OM in selected subgroups. RESULTS: In total, 54.5%, 33.4%, and 12.1% of patients traveled short, intermediate, and long distances, respectively. Residency in rural areas and the receipt of treatment at academic/high-volume centers independently predicted long travel distance. Non-Hispanic black men and Medicaid-insured men were less likely to travel long distances (all P < .001). Overall, traveling a long distance (hazard ratio, 0.87; 95% confidence interval, 0.83-0.92; P < .001) was associated with lower OM risk compared with traveling a short distance. This held true among non-Hispanic white men; privately insured and Medicare-insured men; those who underwent radical prostatectomy, received radiation therapy, and received multimodal strategies; and those who received treatment at academic/ high-volume centers (P < .01), but not among non-Hispanic black men (P 5 .3). Long travel distance was associated with an increased OM in Medicaid-insured patients (P < .001). CONCLUSIONS: An OM benefit was observed among men who traveled long distances for PCa treatment, which is likely to be a reflection of centralization of care and more favorable patient-level characteristics in those travelers. Furthermore, the survival benefit mediated by long travel distances appears to be influenced by baseline socioeconomic, treatment, and facility-level factors.
INTRODUCTION
In ongoing efforts to optimize health care, strategies have focused on reducing treatment costs and improving outcomes. 1 Apart from patient-level factors, such as race/ethnicity, 2, 3 or socioeconomic status, 4 the travel distance to the treating facility is likely to affect the course of diagnosis, subsequent treatment, and disease outcomes. 5 For example, increased travel distance was associated with an increasing likelihood of high-risk prostate 6 and colon cancer 7 at diagnosis. Likewise, patients traveling longer distances were less likely to receive appropriate adjuvant chemotherapy for stage III colon cancer 8 or adjuvant radiation therapy for stage II/III rectal cancer. 9 Conversely, a recent report by Wasif et al, which focused exclusively on patients who underwent surgery, demonstrated that longer travel distance is associated with better long-term cancer outcomes in colon, esophageal, liver, and pancreatic malignancies. 10 One possible explanation for this phenomenon is the ongoing centralization of health care. In the case of prostate cancer (PCa), for example, it is well known that an increasing volume improves outcomes both in surgical patients 11 and in those who receive radiotherapy. 12 To date, there has been no comprehensive assessment of the impact of travel distance on long-term outcomes in patients with PCa, which represents the most common, noncutaneous malignancy in US men and the second most common oncologic cause of death. 13 That given, PCa is 1 of the diseases in which the patient volume is so high that it would be impractical to regionalize all care. Thus, it is important to further understand the relation between travel distance and outcomes to better inform patients and policymakers. On the basis of the available evidence, we hypothesized that: 1) overall mortality (OM) in patients with PCa is associated with the travel distance to the treating facility, and 2) the magnitude of this association may vary based on patient-level, treatment-level, and facility-level characteristics. To test our hypotheses, we queried the National Cancer Data Base (NCDB), which captures approximately 70% of newly diagnosed malignancies in the United States per year and contains approximately 34 million records from national hospital cancer registries.
MATERIALS AND METHODS

Data Source
The NCDB is a hospital-based cancer registry and incorporates data from >1500 Commission on Canceraccredited facilities. Trained data abstractors enter the data, which include demographic and clinical characteristics comparable to those reported in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer registry, 4 as well as detailed tumor information, such as clinical and pathologic staging and treatment pathways. 14 
Study Population
We identified 1,109,267 men who were diagnosed with PCa according to the International Classification of Diseases for Oncology, third edition (code 61.9) within the NCDB from 2004 through 2012. The selection process to define the final study population consisted of several steps (Fig. 1) .
Regarding our primary predictor, namely, travel distance, we specifically excluded patients whose straightline distance between residence and treating facility was 250 miles to reduce bias from patients who were not close to their residence when they sought care. 15 Our selection criteria yielded a total of 775,999 assessable patients who received treatment at 1267 facilities between 2004 and 2012.
Outcomes and Covariates
The primary outcome of the study was OM status, with survival time measured from the date of diagnosis to the date of last follow-up or death (from any cause). The primary predictor was travel distance to the treating facility, which was determined by the Haversine formula, using the distance from the patient's zip code centroid to the reporting facility's street address. 16 Patients were categorized into 3 travel distance strata: <12.5 miles (short distance), from 12.5 to 49.9 miles (intermediate distance), and from 50 to 249.9 miles (long distance), as previously reported. 7, 8, 15 Patient-related covariates consisted of age, race/ethnicity, Charlson-Deyo comorbidity index (CCI), 17 household income quartiles, educational attainment (derived from the number of adults in the patient's zip code who did not graduate from high school), county type of residence, and insurance status. Hospital-related covariates consisted of facility location, facility type, and annual facility caseload quartiles. Disease-related covariates consisted of year of diagnosis, prostate-specific antigen (PSA) level at diagnosis, and biopsy Gleason score. Clinical TNM stage was based on both the American Joint Committee on Cancer Staging Manual (sixth and seventh editions) 18 and the Collaborative Staging System, as previously described. 19 Furthermore, patients were stratified according to the National Comprehensive Cancer Network guidelines as follows 20 : low risk (clinical T1 [cT1]-cT2a tumor, biopsy Gleason score [GS] 6, serum PSA <10 ng/mL), intermediate risk (cT2b-cT2c tumor, biopsy GS 7, PSA 10-20 ng/mL), high risk (cT3a tumor, biopsy GS 8, PSA >20 ng/mL), clinically positive lymph node status (cN1), and clinically positive for metastasis (cM1).
Initial treatment was categorized as radical prostatectomy, radiation therapy, observation, primary androgendeprivation therapy (ADT), or chemotherapy based on the therapeutic approach that the patient received within 180 days of diagnosis. Multimodal therapy was defined as any local treatment to the prostate (radical prostatectomy or radiation therapy) in combination with (neoadjuvant or adjuvant) ADT within 180 days of diagnosis. Likewise, patients who underwent both radical prostatectomy and radiation therapy within the 180-day window (with or without ADT) were considered to have received multimodal treatment.
Statistical Analyses
Our statistical analyses consisted of several steps. First, descriptive analyses were performed to report the distributions of patient-related, hospital-related, and diseaserelated covariates across the 3 travel distance strata. Categorical variables were reported as frequencies and proportions. Continuous variables were reported as means and standard deviations. Differences across the groups were evaluated using chi-square tests and analyses of variance, as appropriate.
Second, multivariable logistic regression analyses tested the independent relation between patient-related, hospital-related, or disease-related covariates and travel Third, Kaplan-Meier curves were used to depict the OM-free survival in the 3 distance strata. Equality of curves were tested using the log-rank test. Moreover, to test the relation between travel distance and OM, we performed multivariable Cox proportional-hazards regression analyses with robust standard errors, 21 which were clustered by facility to account for potential correlations of outcomes at the facility level. The model was adjusted for all available covariates.
Fourth, we performed different sensitivity analyses to confirm the robustness of our results. We repeated multivariable Cox regression analyses using travel distance as a continuous variable to ensure that our findings were not skewed by the definition of travel distance strata, as previously described. 7 Hazard ratios were reported in 10-mile increments. To account for patients whose first course of treatment was only partly conducted at the reporting facility, we performed sensitivity analyses including only those patients who received all first course treatment at the reporting facility (N 5 171,591).
Finally, we performed subgroup analyses to identify the association between long travel distance and OM in selected subsets of patients (stratified by race/ethnicity, household income quartiles, insurance status, facility type, initial treatment, and facility caseload quartiles).
All analyses were performed using SAS statistical software (version 9.4; SAS Institute, Inc, Cary, NC). Statistical comparisons were 2-sided, and all P values < .05 were considered statistically significant.
RESULTS
Descriptive Analyses
Descriptive statistics of the overall study population stratified according to travel distance are reported in Table 1 The median follow-up of patients alive at last follow-up was 58.0 months (interquartile range, 34.9-82.9 months). OM-free survival curves stratified according to patient travel distance are presented in Figure 2 and reveal a significant OM-free survival benefit, specifically for patients with long versus short travel distance (log-rank test: P < .001). In particular, the 5-year and 8-year OM-free survival rates for patients traveling long versus short distances were 92.8% versus 88.5% and 85.1% versus 78.3%, respectively. In the multivariable model (Table 3) , patients who traveled a long distance had a 13% lower OM risk (HR, 0.87; 95% CI, 0.83-0.92; P < .001) compared with their counterparts who traveled a short distance. OM was significantly higher in non-Hispanic black men (HR, 1.12; hospitals (HR, 0.85; 95% CI, 0.80-0.91; P < .001) was associated with significantly lower OM compared with treatment at very-low-volume hospitals.
Sensitivity Analyses
When using travel distance as a continuous variable, the OM risk decreased by 2% for every 10-mile increase in distance (HR, 0.98; 95% CI, 0.97-0.99; P < .001). In addition, among patients who received their entire first course of treatment at the reporting facility, long travel distance was still associated with a significantly lower OM risk compared with short travel distance (HR, 0.82; 95% CI, 0.74-0.92; P < .001).
Association Between Travel Distance and OM Across Different Subgroups
In subgroup analyses (Fig. 3) , long travel distance was associated with more favorable OM rates for nonHispanic whites (HR, 0.87; 95% CI, 0.83-0.91; P < .001), but not for non-Hispanic blacks (HR, 0.95; 95% CI, 0.85-1.06; P 5 .33). Both privately insured patients (HR, 0.88; 95% CI, 0.84-0.92; P < .001) and Medicare beneficiaries (HR, 0.85; 95% CI, 0.82-0.88; P < .001) benefited from a long travel distance. Conversely, among Medicaid beneficiaries, OM was less favorable when they traveled a long distance to the treatment facility (HR, 1.42; 95% CI, 1.18-1.72; P < .001). Regarding different treatment approaches, long travel distance was associated with favorable OM rates in patients who underwent radical prostatectomy (HR, 0.91; 95% CI, 0.84-0.98), radiation therapy (HR, 0.85; 95% CI, 0.79-0.91), multimodal treatment (HR, 0.86; 95% CI, 0.79-0.93), and observation (HR, 0.78; 95% CI, 0.72-0.86; all P < .01), but not for those who received ADT or chemotherapy (P > .1). Finally, OM risk was significantly lower in patients who traveled a long distance to academic/research facilities (HR, 0.86; 95% CI, 0.80-0.92; P < .001) and to veryhigh-volume hospitals (HR, 0.80; 95% CI, 0.74-0.87; P < .001), whereas long travel distance to very-low-volume centers (HR, 0.98; 95% CI, 0.90-1.06; P 5 .56) and to centers with a Community Cancer Program (HR, 0.93; 95% CI, 0.81-1.07; P 5 .30) did not lower the OM risk.
DISCUSSION
In this nationwide cohort of 775,999 North American men with PCa, we identified a correlation between travel distance and OM. Specifically, OM in patients who traveled from 50 to 249.9 miles to their treating facility was decreased by 13% compared with those who traveled <12.5 miles. In addition, the distance traveled was associated with socioeconomic parameters (such as race, insurance, and county type of residence) as well as facilityspecific characteristics (such as annual caseload and facility type). Finally, we observed widespread variation in the OM benefit provided by a long travel distance based on patient and treatment facility characteristics. To date, the impact of distance to the treating facility on OM has not been evaluated in a large-scale, comprehensive setting of a single cancer entity. Our study is the first to report a decrease in OM among patients with PCa who traveled a long distance for their first course of treatment. The association between travel distances and survival outcomes may reflect the consequences of centralization of health care to improve cancer outcomes. 22, 23 Indeed, specifically patients who traveled a long distance to academic/ research facilities and to very-high-volume hospitals had decreases in OM by 14% and 20%, respectively. Evidence is undeniable that there is a relation between increasing hospital caseload and a better outcome after radical prostatectomy. 11 Specifically, robot-assisted laparoscopic prostatectomy has witnessed an "appropriate" centralization to high-volume centers with an associated improvement in perioperative outcomes when controlling for the additional costs. 24, 25 This is reflected by our observation that patients who traveled long distances for radical prostatectomy had more favorable OM outcomes. Taking into consideration that patients who received radiation therapy were less likely to travel long distances for treatment compared with those who underwent surgery, it is intriguing that a similar survival benefit was observed among those who received radiation (and multimodal treatment) who traveled a long distance. Previous studies indicated that patients with PCa were less likely to receive radiation therapy the farther they lived from a treatment center. 26 However, a significant survival benefit was witnessed when patients with high-risk PCa received radiation therapy at high-volume centers. 12 Taken together, our findings, as well as the aforementioned observations from previous reports, may have implications on patient counseling with regard to the potential benefit of seeking health care in a multidisciplinary setting and the advantage of a longer travel distance to do so.
Furthermore, OM is directly influenced by patientlevel characteristics, such as age and comorbidities. Indeed, the patients who traveled long distances were younger and healthier and thus were more likely to live longer. However, there also might be intrinsic, unmeasured factors, which could be mediated by travel distance; for example, individual behavioral and social components, such as the will, financial means, and personal support to overcome the distance to the treatment facility by finding and expending resources to receive better treatment. 27 Arguably, patients of lower socioeconomic status are selected to have worse outcomes already at the baseline because of the lack of particular health-oriented behaviors. It is obvious that those patients who have greater health care orientation might seek care at regionalized facilities with greater annual caseloads, which is likely to increase the effect of better outcomes at larger centers.
We also observed significant socioeconomic disparities in overcoming travel distances for PCa treatment. Non-Hispanic black men, Medicaid beneficiaries, and older and sicker men who had comorbidities were significantly less likely to travel long distances compared with non-Hispanic white men, privately insured individuals, younger patients, and those without comorbidities, respectively. Race and socioeconomic status are well known indicators of disparities in PCa care and outcomes. For example, compared with non-Hispanic whites, blacks were associated with significant disadvantages when undergoing radical prostatectomy for localized PCa. 3 However, these disparities presumably are more complex and not just mirrored in racial variations but, rather, are driven by collinear factors, such as the insurance status. 2 In a retrospective SEER study, noninsured patients and Medicaid beneficiaries were more likely to be diagnosed at a higher stage or to be undertreated, specifically those with high-risk disease. 28 Socioeconomic status, based on income, education, and insurance, is associated with the receipt and quality of cancer screening and treatment. Likewise, it is directly related to social and/or financial resources to overcome the inherent complexities of multidisciplinary cancer care. 29, 30 Travel distance seems to be an additional metric functioning as a surrogate variable to reveal health care disparities. Arguably, it is impossible to regionalize all of PCa care in a country like the United States, and our findings may emphasize the downside of those attempts. Long travel distances have implications on the coordination and continuity of care, but this might be more relevant in less populated regions, such as in the East South Central or Western census region.
Non-Hispanic black men and Medicaid beneficiaries were less likely to travel long distances for treatment. However, even when they did so, this did not translate into a survival benefit, as observed in their non-Hispanic white and privately or Medicare-insured counterparts. This suggests that: 1) access to care is seemingly uneven between Medicare and Medicaid beneficiaries; and 2) even if the travel burden is overcome, the quality and provided spectrum of health care is significantly different between patients with various insurance statuses. The same might explain the differences between non-Hispanic black and non-Hispanic white patients. This suggests a novel aspect of disparity in access to health care and suggests severe health-related disadvantages in specific subgroups. Centralization of care is fulfilling its purpose only as long as every individual, regardless of socioeconomic status and personal background, has access to centers of excellence and as long as it does not worsen the existing disparities between those who are treated at large academic centers versus low-volume community hospitals. It is noteworthy that a Medicare analysis of 3 high-risk surgeries demonstrated that black patients lived closer to high-quality hospitals than white patients but were 25% more likely to undergo surgery at low-quality institutions. 31 Indeed, disparities are likely to be driven by both uneven access to care and intrinsic, patient-level factors, such as personal beliefs and cultural background toward health care orientation. 32 The observed findings have to be interpreted within the limitations inherent in our study design. First, only Commission on Cancer-accredited facilities contributed to the NCDB data collection; thus, the sample was not Original Article population-based. However, we believe that the findings are likely to be generalizable, because comparisons with patients who had PCa from the SEER Program database indicated that they were remarkably similar in disease severity and demographic characteristics. 4 Second, because we focused on PCa, our findings might not be applicable to other malignancies with different natural histories and treatment pathways. Third, our study population included patients who received only a part of the first course of treatment at the reporting facility. This might have caused a certain bias considering that patients subsequently received treatment elsewhere, which also might have had an impact on outcomes. However, we performed a sensitivity analysis including only patients who received their complete first course of treatment at the reporting facility, and the results remained robust. Fourth, patient-related factors, such as patient motivation itself or social support of caregivers or spouses, are not captured by the NCDB. In addition, the preference and influence of primary general practitioners might channel patients' choices to overcome travel burdens. Thus, whether a patient voluntarily took on the burden of a longer travel distance, bypassing closer hospitals along the way, could not be measured. Fifth, we were not able to assess provider density. Because of highly variable national geography in the United States, travel distance in rural states might not be entirely comparable to travel in urban states with higher and denser populations. To overcome this limitation, our multivariable models were adjusted for county level, indicating metropolitan, urban, or rural status. Finally, misclassification bias using zip code centroids for patient residence and reporting facility may have resulted in underestimation or overestimation of travel distance.
Conclusions
In summary, we observed an OM benefit among men who traveled a long distance for PCa treatment. This is likely caused by higher quality of care at centralized academic and high-volume facilities, where these patients usually end up receiving their treatment. Moreover, this survival benefit might be a reflection of the more favorable patient-level characteristics of these individuals. Specifically, we observed concerning socioeconomic disparities in the access to care regarding a higher travel burden, which translated into less favorable OM outcomes for non-Hispanic black men and nonprivately insured patients. Our results suggest not only that patients who travel longer distances live longer but that, even if they are going the extra mile, their OM outcomes are likely to be influenced by baseline socioeconomic and facility-specific factors.
